Evidence map›Paper›PMID 41059462›Full record

ReviewFrontiers in veterinary science2025

Osteosarcoma of the appendicular skeleton in dogs: consensus and guidelines.

Gerry Polton, Juan F Borrego, Francisco Clemente-Vicario, Craig A Clifford, Dariusz Jagielski, Martin Kessler, Tetsuya Kobayashi, Didier Lanore, Felisbina L Queiroga, Lucas Rodrigues and 3 more

Abstract readReview
In one paragraph

Review in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Gerry PoltonNorth Downs Specialist Referrals, Bletchingley, United Kingdom.
Juan F BorregoHospital Aúna Especialidades Veterinarias IVC-Evidensia, Valencia, Spain.
Francisco Clemente-VicarioLa Merced Veterinary Specialists, Alicante, Spain.
Craig A CliffordBluepearl, Malvern, PA, United States.
Dariusz JagielskiFaculty of Biological and Veterinary Sciences, Veterinary Institute, Nicolaus Copernicus University, Toruń, Poland.
Martin KesslerDepartment of Clinical Oncology, Tierklinik Hofheim, Hofheim, Germany.
Tetsuya KobayashiJapan Small Animal Cancer Center, Tokorozawa-City, Japan.
Didier LanoreOncology Unit, Clinique Hopia, Guyancourt, France.
Felisbina L QueirogaCECAV, University of Trás-os-Montes and Alto Douro, Vila Real, Portugal.
Lucas RodriguesEstima Diagnósticos e Especialidades, Taubaté, Brazil.
Annika Tranaeus RoweEvidensia Specialist Animal Hospital Strömsholm, Strömsholm, Sweden.
Péter VajdovichDepartment of Physiology and Oncology, University of Veterinary Medicine, Budapest, Hungary.
Philip J BergmanVeterinary & Cancer Immunotherapy Programs, Focused Ultrasound Foundation, Charlottesville, VA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteosarcoma (OSA) in dogs poses a clinical challenge to veterinary practitioners across the globe. As knowledge evolves, so too do clinical practices. However, there remain uncertainties and controversies. There is value for the veterinary community at large in the generation of a contemporary wide-ranging guideline document. The aim of this project was therefore to assimilate the available published knowledge into a single accessible referenced resource and to provide expert clinical guidance to support professional colleagues as they navigate current OSA challenges and controversies. Primary bone tumors are common in dogs. The history and clinical signs relate to the anatomic site of the tumor. Most canine patients present with a sudden-onset lameness that can appear to improve temporarily in response to analgesia and rest. Most patients do not have detectable metastasis at the time of diagnosis, but most canine patients do develop metastasis within months without appropriate therapy. Surgical resection using wide margins is currently the mainstay of therapy for the local control of the primary tumor. Most commonly, this comprises limb amputation in dogs, but not all dogs are considered good candidates. Anti-metastatic therapy is vital in dogs if surgery is going to offer a good chance of achieving a durable benefit. While there are many limb-sparing and palliative therapy options for dogs with OSA, most have not been shown to achieve superior outcomes compared with amputation and adjuvant chemotherapy. There is a role for radiotherapy in the palliative treatment of OSA. Immunotherapy should be considered a developing treatment modality-multiple immunotherapeutic approaches have yielded positive results in dogs in small experimental studies. It is hoped that this document will serve as a useful resource to practitioners all over the world, to help them better understand this disease and provide the best options for patients to extend quality of life and survival, either within the primary care or referral hospital setting.

Indexed as

canineguidelines & recommendationsosteosarcomaprognosistreatment

Identifiers

PMID41059462
PMCPMC12498955

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.